98%
921
2 minutes
20
Introduction: Myasthenia Gravis (MG) is an autoimmune disease. The characteristic symptoms of the disease are muscle weakness and fatigue. These symptoms affect de oral muscles causing dysarthria, affecting about 60% of patients with disease progression.
Purpose: Describe the speech pattern of patients with MG and comparing with healthy controls (HC).
Material And Methods: Case-control study. Participants were divided in MG group (MGG) with 38 patients MG diagnosed and HC with 18 individuals matched for age and sex. MGG was evaluated with clinical and motor scales and answered self-perceived questionnaires. Speech assessment of both groups included: recording of speech tasks, acoustic and auditory-perceptual analysis.
Results: In the MGG, 68.24% of the patients were female, with average age of 50.21 years old (±16.47), 14.18 years (±9.52) of disease duration and a motor scale of 11.19 points (±8.79). The auditory-perceptual analysis verified that 47.36% ( = 18) participants in MGG presented mild dysarthria, 10.52% ( = 4) moderate dysarthria, with a high percentage of alterations in phonation (95.2%) and breathing (52.63%). The acoustic analysis verified a change in phonation, with significantly higher shimmer values in the MGG compared to the HC and articulation with a significant difference between the groups for the first formant of the /iu/ ( = <.001). No correlation was found between the diagnosis of speech disorder and the dysarthria self-perception questionnaire.
Conclusion: We found dysarthria mild in MG patients with changes in the motor bases phonation and breathing, with no correlation with severity and disease duration.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/14015439.2020.1834614 | DOI Listing |
J Autoimmun
September 2025
Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany; Neuroscience Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate Member of Freie Un
Objective: New therapeutic options have recently emerged for patients with highly active, acetylcholine receptor antibody-positive (AChR-Ab) generalized myasthenia gravis (gMG), including fast-acting, endplate-protective agents such as complement C5 inhibitors (C5-I) and neonatal Fc receptor inhibitors (FcRn-I). However, objective biomarkers beyond clinical scoring systems are lacking to guide individualized treatment decisions.
Methods: In this exploratory, prospective real-world study, we assessed serum calprotectin (sCLP) and serum neurofilament light chain (sNfL) levels in a total of 22 AChR-Ab gMG patients, who were treatment-naïve for either C5-I or FcRn-I.
Zhonghua Jie He He Hu Xi Za Zhi
September 2025
Neuromuscular diseases are often accompanied by various types of sleep-related breathing disorders, which can exacerbate the underlying condition and are associated with a poor prognosis. Early identification is essential, and interventions such as non-invasive ventilation, oxygen therapy, and respiratory rehabilitation should be initiated promptly to mitigate disease progression and improve outcomes. Nevertheless, the rates of missed and misdiagnosed cases remain common in clinical practice.
View Article and Find Full Text PDFBackground: Growing evidence suggests a close association between circulating micronutrient levels and neuroimmune diseases. Nevertheless, the causal relationship between them remains unclear. Furthermore, due to confounding factors, many micronutrients implicated in these diseases remain unidentified.
View Article and Find Full Text PDFJ Neurol
September 2025
Department of Neurology, Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing, China.
Background And Purpose: Efgartigimod has demonstrated efficacy in generalized myasthenia gravis (gMG) in both clinical trials and real-world studies. However, factors influencing early response have been less reported. This study aimed to evaluate the efficacy of efgartigimod in a multicenter gMG cohort and to identify the clinical factors associated with early therapeutic response.
View Article and Find Full Text PDFPhotodiagnosis Photodyn Ther
September 2025
China Medical University, Hsin-Chu Hospital. Electronic address:
Background: Managing stage IV thymoma with pleural spread or recurrence remains a complex clinical challenge. While complete resection is considered essential for achieving long-term survival, its feasibility and outcomes vary. Inspired by surgical strategies used in malignant pleural mesothelioma, we applied a multimodal approach combining extensive thymectomy, cytoreductive lung-preserving pleurectomy/decortication, and intraoperative photodynamic therapy (PDT) to enhance local control and survival outcomes.
View Article and Find Full Text PDF